Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (21-30 of 350) with videos related to

Pageof 35
Sort By:
The New England Journal of Medicine|February 2, 1984
Cimetidine for herpes zosterG M Mavligit, M Talpaz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancersN J Donato, M Talpaz
Blood|May 15, 1995
Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trialH M Kantarjian, M Talpaz
Seminars in Oncology|December 1, 1994
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemiaH M Kantarjian, M Talpaz
Stem Cells (Dayton, Ohio)|October 1, 1993
Therapy of chronic myelogenous leukemiaH M Kantarjian, M Talpaz
Leukemia & Lymphoma|August 1, 1993
Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemiaZ Estrov, R Kurzrock, M Talpaz
Seminars in Hematology|July 1, 1995
Cytokines and their antagonists in myeloid disordersZ Estrov, R Kurzrock, M Talpaz
Cancer|January 15, 1995
Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell linesR Kurzrock, S Ku, M Talpaz
Seminars in Oncology|August 1, 1995
Treatment of chronic myelogenous leukemiaS Giralt, H Kantarjian, M Talpaz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndromeR Kurzrock, E Estey, M Talpaz
Pageof 35

Showing results (21-30 of 350) with videos related to

Sort By:
Pageof 35
The New England Journal of Medicine|February 2, 1984
Cimetidine for herpes zosterG M Mavligit, M Talpaz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancersN J Donato, M Talpaz
Blood|May 15, 1995
Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trialH M Kantarjian, M Talpaz
Seminars in Oncology|December 1, 1994
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemiaH M Kantarjian, M Talpaz
Stem Cells (Dayton, Ohio)|October 1, 1993
Therapy of chronic myelogenous leukemiaH M Kantarjian, M Talpaz
Leukemia & Lymphoma|August 1, 1993
Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemiaZ Estrov, R Kurzrock, M Talpaz
Seminars in Hematology|July 1, 1995
Cytokines and their antagonists in myeloid disordersZ Estrov, R Kurzrock, M Talpaz
Cancer|January 15, 1995
Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell linesR Kurzrock, S Ku, M Talpaz
Seminars in Oncology|August 1, 1995
Treatment of chronic myelogenous leukemiaS Giralt, H Kantarjian, M Talpaz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndromeR Kurzrock, E Estey, M Talpaz
Pageof 35